Erythropoietin gene expression in renal carcinoma is considerably more frequent than paraneoplastic polycythemia
Open Access
- 19 July 2007
- journal article
- research article
- Published by Wiley in International Journal of Cancer
- Vol. 121 (11) , 2434-2442
Abstract
Signalling by erythropoietin (EPO) is increasingly recognised as a relevant mechanism in tumour biology, potentially leading to enhanced proliferation, angiogenesis and therapy resistance. Paraneoplastic polycythemia by cancerous overproduction of EPO is a rare event, but most frequently seen in patients with renal cell carcinoma (RCC). The majority of clear cell RCC displays a strong activation of the transcription factor regulating EPO, the Hypoxia‐inducible Factor (HIF). Therefore, it is unclear why only a small minority of patients develop polycythemia. We studied 70 RCC for EPO gene and HIFα isoform expression. 34% of all RCC showed expression of EPO mRNA in RNase protection assays, which were almost exclusively of the clear cell type. Only 1 patient presented with polycythemia. In situ hybridisation revealed that expression of EPO was in the tumour cells. Expression of EPO mRNA was always associated with activation of HIF, which could involve HIF‐1α and/or HIF‐2α. The frequency of EPO gene expression in RCC is therefore much higher than the prevalence of polycythemia. Furthermore, activation of HIF appears necessary for EPO gene expression in RCC, but is clearly not the only determinant. Further to the reported expression of EPO receptors in tumour tissues, the finding of widespread expression of EPO in RCC supports the recent notion of an involvement of this system in paracrine or autocrine effects of tumour cells.Keywords
This publication has 58 references indexed in Scilit:
- The Hypoxia-Inducible Factor 2 α N-Terminal and C-Terminal Transactivation Domains Cooperate To Promote Renal Tumorigenesis In VivoMolecular and Cellular Biology, 2007
- Acute postnatal ablation of Hif-2 α results in anemiaProceedings of the National Academy of Sciences, 2007
- Contrasting Properties of Hypoxia-Inducible Factor 1 (HIF-1) and HIF-2 in von Hippel-Lindau-Associated Renal Cell CarcinomaMolecular and Cellular Biology, 2005
- Differentiating the functional role of hypoxia‐inducible factor (HIF)‐1α and HIF‐2α (EPAS‐1) by the use of RNA interference: erythropoietin is a HIF‐2α target gene in Hep3B and Kelly cellsThe FASEB Journal, 2004
- von Hippel-Lindau Tumor Suppressor Protein and Hypoxia-Inducible Factor in Kidney CancerAmerican Journal of Nephrology, 2004
- Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trialThe Lancet, 2003
- Widespread, hypoxia‐inducible expression of HIF‐2α in distinct cell populations of different organsThe FASEB Journal, 2002
- Disruption of oxygen homeostasis underlies congenital Chuvash polycythemiaNature Genetics, 2002
- Dermatomyositis and erythrocytosis associated with hepatocellular carcinomaJournal of Gastroenterology and Hepatology, 2002
- Gene Expression of Erythropoietin in Renal Cell Carcinoma.Internal Medicine, 1999